Gilead Sciences supplies Yescarta and Tecartus CAR-T to Clatterbridge
- The Clatterbridge Cancer Centre NHS Foundation Trust
- North West
- Direct award
- 19 October 2026 to 19 October 2026
The Clatterbridge Cancer Centre NHS Foundation Trust bought two CAR-T therapies, Yescarta and Tecartus, from Gilead Sciences. Yescarta is the medicine axicabtagene ciloleucel, and Tecartus is brexucabtagene autoleucel.
The trust awarded the £893,953 contract to Gilead directly, without a competition. The contract was due to start and end in October 2026.
- What
- Medicines supply
- Supplier
- Gilead Sciences
- Value
- £893,953
- How it was bought
- Direct award
- Dates and next
- Oct 2026 to Oct 2026